Arcturus Therapeutics (NASDAQ:ARCT) Trading 5.9% Higher

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was up 5.9% during mid-day trading on Thursday . The company traded as high as $33.63 and last traded at $32.89. Approximately 156,505 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 487,368 shares. The stock had previously closed at $31.06.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ARCT shares. Canaccord Genuity Group reduced their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a research note on Friday, May 10th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. Finally, William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $64.86.

Arcturus Therapeutics Stock Down 1.9 %

The business’s 50 day simple moving average is $30.90 and its 200 day simple moving average is $32.40.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) EPS for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.17. The business had revenue of $38.01 million during the quarter, compared to analysts’ expectations of $22.12 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. As a group, sell-side analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -4.39 earnings per share for the current fiscal year.

Insider Transactions at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 26,000 shares of Arcturus Therapeutics stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the completion of the sale, the chief operating officer now owns 447,448 shares in the company, valued at approximately $17,902,394.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 52,114 shares of company stock worth $1,955,824. 13.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Boston Partners purchased a new position in Arcturus Therapeutics during the 1st quarter valued at about $580,000. Teachers Retirement System of The State of Kentucky purchased a new position in Arcturus Therapeutics during the 1st quarter valued at about $517,000. Tidal Investments LLC purchased a new position in Arcturus Therapeutics during the 1st quarter valued at about $232,000. Jacobs Levy Equity Management Inc. increased its position in Arcturus Therapeutics by 111.0% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 95,924 shares of the biotechnology company’s stock valued at $3,239,000 after purchasing an additional 50,470 shares during the period. Finally, Caxton Associates LP purchased a new position in Arcturus Therapeutics during the 1st quarter valued at about $202,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.